Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;13:6309–6317. doi: 10.2147/CMAR.S314060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Xu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The brain enhanced MRI of a 61-year-old woman with non-small cell lung cancer and EGFR 21L858R mutation before and after EGFR-TKI treatment. The positions indicated by the arrows are the lesions. (A) Contrast-enhanced T1-weighted MR image at baseline. (B) Contrast-enhanced T2-weighted MR image at baseline. (C) Contrast-enhanced T1-weighted MR image after icotinib (first-generation EGFR-TKI) treatment and whole brain radiotherapy (prescription dose and fraction schedule of 30Gy/10F) treatment for 1 month. (D) Contrast-enhanced T2-weighted MR image after icotinib and whole brain radiotherapy treatment for 1 month.